| LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration M Deng, X Gui, J Kim, L Xie, W Chen, Z Li, L He, Y Chen, H Chen, W Luo, ... Nature 562 (7728), 605-609, 2018 | 203 | 2018 |
| Vesicular antibodies: a bioactive multifunctional combination platform for targeted therapeutic delivery and cancer immunotherapy X Liu, C Liu, Z Zheng, S Chen, X Pang, X Xiang, J Tang, E Ren, Y Chen, ... Advanced Materials 31 (17), 1808294, 2019 | 73 | 2019 |
| Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development X Gui, M Deng, H Song, Y Chen, J Xie, Z Li, L He, F Huang, Y Xu, ... Cancer immunology research 7 (8), 1244-1257, 2019 | 61 | 2019 |
| An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency C Shen, M Zhang, Y Chen, L Zhang, G Wang, J Chen, S Chen, Z Li, F Wei, ... Theranostics 9 (1), 210, 2019 | 39 | 2019 |
| Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells H Chen, Y Chen, M Deng, S John, X Gui, A Kansagra, W Chen, J Kim, ... Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 31 | 2020 |
| Efficient mAb production in CHO cells with optimized signal peptide, codon, and UTR M You, Y Yang, C Zhong, F Chen, X Wang, T Jia, Y Chen, B Zhou, Q Mi, ... Applied microbiology and biotechnology 102, 5953-5964, 2018 | 31 | 2018 |
| Research progress and applications of nanobody in human infectious diseases Y Mei, Y Chen, JP Sivaccumar, Z An, N Xia, W Luo Frontiers in pharmacology 13, 963978, 2022 | 30 | 2022 |
| A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16. V5 L Xia, Y Xian, D Wang, Y Chen, X Huang, X Bi, H Yu, Z Fu, X Liu, S Li, ... Scientific reports 6 (1), 19042, 2016 | 21 | 2016 |
| Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans GP Wen, L He, ZM Tang, SL Wang, X Zhang, YZ Chen, X Lin, C Liu, ... Nature Communications 11 (1), 3971, 2020 | 20 | 2020 |
| A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys C Kang, L Xia, Y Chen, T Zhang, Y Wang, B Zhou, M You, Q Yuan, ... Protein & Cell 9 (1), 130-134, 2018 | 16 | 2018 |
| Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection X Ye, X Gui, DC Freed, Z Ku, L Li, Y Chen, W Xiong, X Fan, H Su, X He, ... PLoS pathogens 15 (7), e1007914, 2019 | 14 | 2019 |
| A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential B Zhou, L Xu, R Zhu, J Tang, Y Wu, R Su, Z Yin, D Liu, Y Jiang, C Wen, ... Antiviral Research 161, 28-35, 2019 | 12 | 2019 |
| Blocking LAIR1 signaling in immune cells inhibits tumor development J Xie, X Gui, M Deng, H Chen, Y Chen, X Liu, Z Ku, L Tan, R Huang, Y He, ... Frontiers in immunology 13, 996026, 2022 | 10 | 2022 |
| A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy Y Wang, Y Mei, Z Ao, Y Chen, Y Jiang, X Chen, R Qi, B Fu, J Tang, ... Antiviral Research 199, 105265, 2022 | 5 | 2022 |
| Novel monkey mAbs induced by a therapeutic vaccine targeting the hepatitis B surface antigen effectively suppress hepatitis B virus in mice Y Chen, X Xiang, R Qi, Y Wang, Y Huang, M You, Y Xian, Y Wu, R Fu, ... Antibody Therapeutics 4 (4), 197-207, 2021 | 2 | 2021 |
| Efficient development of a stable cell pool for antibody production using a single plasmid Y Yang, M You, F Chen, T Jia, Y Chen, B Zhou, Q Mi, Z An, W Luo, N Xia The journal of biochemistry 163 (5), 391-398, 2018 | 1 | 2018 |
| 稳定表达可视化 hFcRn 的 MDCK 细胞株构建 康赐明， 陈远志， 王一文， 周兵， 游敏， 罗文新， 夏宁邵 生物技术 2, 123-128, 2017 | 1 | 2017 |
| Nanobodies in Human Infectious Diseases: A Comprehensive Review of Research and Applications WL Ziyou Chen, Yuanzhi Chen, Zhiren Zeng, Na Yuan, Yaxian Mei, Zhenzhen Zhu Novapublishers, 2024 | | 2024 |
| A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration Y Jiang, X Chen, X Ye, C Wen, T Xu, C Yu, W Ning, G Wang, X Xiang, ... Advanced Science, 2305316, 2024 | | 2024 |
| A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo M You, F Chen, C Yu, Y Chen, Y Wang, X Liu, X Guo, B Zhou, X Wang, ... Frontiers in Pharmacology 14, 1213726, 2023 | | 2023 |
Zhiqiang AnProfessor of Molecular Medicine, University of Texas Health Science Center at HoustonVerified email at uth.tmc.edu
